New protein treatment hopes to repair brain damage in rare disease
NCT ID NCT06765733
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 35 times
Summary
This early-phase trial is testing a new drug called Aleeto, a nerve repair protein, in 20 people with Multiple System Atrophy (MSA), a rare and progressive brain disorder. The study aims to see if Aleeto is safe and tolerable, and whether it shows any signs of helping with symptoms. Participants will receive the drug via injection into the spine or vein.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SYSTEM ATROPHY - PARKINSONIAN SUBTYPE (MSA-P) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100070, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aleeto (a nerve repair protein derived from stem cells)
What this could lead to
If it works, this could point toward a treatment that slows or repairs nerve damage in Multiple System Atrophy, a rare and devastating disease.
What could go wrong
This is a very early, small trial (20 people) focused on safety, not proof of effectiveness. The treatment may not work or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.